EXTENDED REPORT

Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF

C Eriksson¹, S Engstrand², K-G Sundqvist¹, S Rantapää-Dahlqvist²

¹ Department of Clinical Immunology, University Hospital, Umeå, Sweden
² Department of Rheumatology, University Hospital, Umeå

Correspondence to:
Dr S Rantapää Dahlqvist
Department of Rheumatology, University Hospital, S-901 85 Umeå, Sweden; solbritt.rantapaa.dahlqvist{at}medicin.umu.se

Background: Research on autoantibody formation in patients treated with TNF inhibitors has produced contradictory results.

Objective: To study the prevalence of autoantibodies in patients with rheumatoid arthritis treated with the TNF inhibitor infliximab.

Methods: 53 patients (48 female, 11 male) treated with infliximab for rheumatoid arthritis were followed for autoantibody production before treatment and after 14, 30, and 54 weeks. Six patients treated with etanercept were studied for comparison. The analyses included antibodies against nuclear antigens (ANA), extractable nuclear antigens, double stranded (ds)DNA (by ELISA, IIF on Crithidia luciliae for IgM and IgG, and Farr assay), nucleosomes, cardiolipin, smooth muscle, mitochondria, proteinase 3, and myeloperoxidase antigens.

Results: The number of patients treated with infliximab who developed antibodies against dsDNA of both IgG and IgM class (tested by IIF) increased significantly. The prevalence of patients positive for IgG class increased to 66% at 30 weeks and 45% at 54 weeks, and of IgM class to 85% and 70%, respectively. The titre and number of patients expressing antibodies against nucleosomes and ANA also increased significantly. The number of rheumatoid factor or anticardiolipin positive patients was stable and there was no increase in antibodies against the other antigens. A lupus-like syndrome was seen in one patient. No patient treated with etanercept developed any of these autoantibodies.

Conclusions: Patients treated with infliximab may develop anti-dsDNA antibodies of both IgM and IgG class, anti-nucleosome antibodies, and ANA, with a gradual increase until 30 weeks.

Abbreviations: aCL, anticardiolipin; ACR, American College of Rheumatology; ANA, antinuclear antibodies; anti-dsDNA, anti-double stranded DNA antibodies; ENA, extractable nuclear antigens; IIF, indirect immunofluorescence; TNF, tumour necrosis factor

Keywords: TNF inhibitor; anti-dsDNA; antinucleosome antibodies; rheumatoid arthritis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Priori, R, Alessandri, C, Magrini, L, Cassara, E A M, Ceccarelli, F, Modesti, M, Croia, C, Bombardieri, M, Valesini, G (2009). Nucleosome accumulation and reduction of C-reactive protein are associated with the generation of anti-nuclear antibodies in patients with rheumatoid arthritis treated with adalimumab, but not with etanercept. Ann Rheum Dis 68: 1514-1516 [Full Text]  
• Combe, B, Codreanu, C, Fiocco, U, Gaubitz, M, Geusens, P P, Kvien, T K, Pavelka, K, Sambrook, P N, Smolen, J S, Khandker, R, Singh, A, Wajdula, J, Fatenejad, S, for the Etanercept European Investigators Network, (2009). Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis 68: 1146-1152 [Abstract] [Full Text]  
• Williams, E. L., Gadola, S., Edwards, C. J. (2009). Anti-TNF-induced lupus. Rheumatology (Oxford) 48: 716-720 [Abstract] [Full Text]  
• WELLS, G. A. (2009). Patient-Driven Outcomes in Rheumatoid Arthritis. The Journal of Rheumatology Supplement 82: 33-38 [Abstract] [Full Text]  
• Kaiser, T., Moessner, J., Patel, K., McHutchison, J. G, Tillmann, H. L (2009). Life threatening liver disease during treatment with monoclonal antibodies. BMJ 338: b508-b508 [Full Text]  
• Aringer, M, Smolen, J. (2009). TNF inhibition in SLE: where do we stand?. Lupus 18: 5-8  
• Baek, H. J., Zhang, L., Jarvis, L. B., Gaston, J. S. H. (2008). Increased IL-4+ CD8+ T cells in peripheral blood and autoreactive CD8+ T cell lines of patients with inflammatory arthritis. Rheumatology (Oxford) 47: 795-803 [Abstract] [Full Text]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]  
• Maria Lizzio, M., Peluso, G., Zoli, A., Gremese, E., Tolusso, B., Ferraccioli, G. (2007). Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset. Ann Rheum Dis 66: 427-428 [Full Text]  
• Sweet, B. V. (2006). Abatacept.. Am J Health Syst Pharm 63: 2065-2077 [Abstract] [Full Text]  
• DeBandt, M (2006). Lessons for lupus from tumour necrosis factor blockade. Lupus 15: 762-767 [Abstract]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Emery, P, Keystone, E C, Schiff, M H, van Riel, P L C M, Weinblatt, M E, Weisman, M H (2006). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 65: iii2-iii15 [Full Text]  
• Pucino, F. Jr., Harbus, P. T., Goldbach-Mansky, R. (2006). Use of biologics in rheumatoid arthritis: Where are we going?. Am J Health Syst Pharm 63: S19-S41 [Abstract] [Full Text]  
• den Broeder, A A, de Jong, E, Franssen, M J A M, Jeurissen, M E C, Flendrie, M, van den Hoogen, F H J (2006). Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis 65: 760-762 [Abstract] [Full Text]  
• Pallotta, P., Cianchini, G., Ruffelli, M., Puddu, P. (2006). Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis. Rheumatology (Oxford) 45: 116-117 [Full Text]  
• De Rycke, L, Baeten, D, Kruithof, E, Van den Bosch, F, Veys, E M, De Keyser, F (2005). The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. Lupus 14: 931-937 [Abstract]  
• Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, J W J, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J (2005). Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 64: iv2-iv14 [Full Text]  
• Mukhtyar, C, Luqmani, R (2005). Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann Rheum Dis 64: iv31-iv36 [Abstract] [Full Text]  
• Yazdani-Biuki, B, Stadlmaier, E, Mulabecirovic, A, Brezinschek, R, Tilz, G, Demel, U, Mueller, T, Brickmann, K, Graninger, W B, Brezinschek, H-P (2005). Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 64: 1224-1226 [Abstract] [Full Text]